GLP-1 cancer-risk signal disappears when compared with metformin, review notes
The most-cited study, a 1.65 million-patient JAMA Network Open cohort, found lower risk in 10 of 13 obesity-linked cancers only against insulin.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 4 03:00 ETSource: Yahoo Health
The wire
- 01The 2024 JAMA Network Open analysis of 1,651,452 patients with type 2 diabetes found GLP-1 drugs associated with lower risk in 10 of 13 obesity-associated cancers versus insulin, but no significant reduction versus metformin.
- 02Clinicians fielding cancer-prevention questions can note the insulin-only signal may reflect insulin's growth-factor biology rather than GLP-1 protection; the medullary thyroid cancer contraindication still stands absolutely.
- 03Almost all data are observational and cannot establish cause; retatrutide, still investigational and trial-only, has no cancer data of its own.
From the source
Read at health.yahoo.comCould Retatrutide Lower Cancer Risk? Here’s What the Biggest Study Really Found
Retatrutide is an investigational, once weekly triple hormone receptor agonist, acting on the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. It is being tested mainly for obesity, alongside type 2 diabetes, sleep apnea, and liver, heart, and kidney conditions, and has produced dramatic weight loss in trials.